Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged pharmaceuticals · clear
Source: https://www.greyb.com/blog/drug-patents-expiring-2024/ The pharmaceutical industry is undergoing a important phase as numerous patents for key drugs are slated to expire in 2024. This impending expiration of patents signals a significant shift in…
In late August of this year, our ANDA Intelligence 2023 Report was released, a comprehensive study, covering the Hatch-Waxman litigation within US district courts. The report focused on the period from July 1, 2018, through June 30, 2023, encapsulating a…
In a significant ruling on December 19, 2023, the German patent court invalidated a crucial patent that formed the core of CureVac's lawsuit against BioNTech, causing a notable impact on the stock market. Following Presiding Judge Walter Schramm's…
The Biden administration is exploring the use of "march-in" rights established in the 1980 Bayh-Dole Act , which has never been utilized before. This provision allows federal agencies to request licensing agreements for inventions developed under…
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This report series shines a spotlight on the intricate web of ANDA (Abbreviated New Drug Application) cases and…
We are proud to announce that tomorrow marks the release of the fourth edition of our ANDA Litigation Intelligence Report. This year's report is an in-depth compilation that includes not just data and rankings but also a thorough analysis of…
In the intricate world of pharmaceuticals, where innovation meets regulation, ANDA litigation stands as a pivotal battleground. Abbreviated New Drug Application (ANDA) litigation plays a crucial role in determining the fate of generic drugs in the market.…
In the realm of pharmaceuticals, the approval process for generic and brand-name drugs holds significant importance. The Hatch-Waxman Act, a pivotal piece of legislation, governs these processes, ensuring a delicate balance between innovation,…
Abbreviated New Drug Application (ANDA) litigation stands at the crossroads of pharmaceutical innovation and legal prowess. As generic drug companies seek to enter the market while facing patent challenges from brand-name giants, the role of skilled…
In the world of pharmaceuticals, access to affordable generic drugs is crucial for ensuring cost-effective healthcare solutions. The Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act, plays a pivotal role in…
The landscape of patent litigation is ever-evolving, and the first half of 2023 has been no exception. The dynamics of patent litigation are complex, and its trends can be influenced by various elements that interact with each other. Factors such as…
Written by : Rhett D. Ramsey & Michael L. Fuller In Sanofi-Aventis Deutschland GmbH v. Mylan Pharm. Inc., Case No. 2021-1981, the Federal Circuit reversed an obviousness determination by the PTAB. At issue was Sanofi’s reissued U.S. Patent No.…
